Filing Details

Accession Number:
0001209191-18-009413
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-02-12 21:00:07
Reporting Period:
2018-02-09
Accepted Time:
2018-02-12 21:00:07
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1604464 Atara Biotherapeutics Inc. ATRA () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1403571 D Heather Turner C/o Atara Biotherapeutics, Inc.
611 Gateway Boulevard, Suite 900
South San Francisco CA 94080
Former Evp, Gc & Sec. No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2018-02-09 4,596 $36.63 77,112 No 4 S Direct
Common Stock Disposition 2018-02-09 4,123 $37.38 72,989 No 4 S Direct
Common Stock Disposition 2018-02-09 600 $38.63 72,389 No 4 S Direct
Common Stock Disposition 2018-02-09 733 $39.66 71,656 No 4 S Direct
Common Stock Disposition 2018-02-09 600 $40.62 71,056 No 4 S Direct
Common Stock Disposition 2018-02-09 1,562 $41.69 69,494 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Footnotes
  1. Transaction pursuant to Rule 10b5-1 Plan adopted September 23, 2016.
  2. The price in Column 4 is a weighted average sale price. The prices actually received ranged from $36.00 to $37.00. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  3. The price in Column 4 is a weighted average sale price. The prices actually received ranged from $37.05 to $38.05. The reporting person will provide to theissuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  4. The price in Column 4 is a weighted average sale price. The prices actually received ranged from $38.10 to $39.05. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  5. The price in Column 4 is a weighted average sale price. The prices actually received ranged from $39.15 to $39.95. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  6. The price in Column 4 is a weighted average sale price. The prices actually received ranged from $40.20 to $41.05. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  7. The price in Column 4 is a weighted average sale price. The prices actually received ranged from $41.35 to $41.80. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.